ClinicalTrials.gg
RecruitingNCT07827183AI-LUNGUpdated Sep 18, 2026

AI-Personalized Discharge Education for Patients After Lung Cancer Surgery

An interventional study of AI-Personalized Discharge Education and Routine Discharge Education in Lung Cancer (Diagnosis), sponsored by Xiamen University. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-18.

Sponsored by Xiamen University · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Started Aug 2026; still recruiting 2 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
156
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

This randomized controlled trial evaluates the effect of artificial intelligence (AI)-personalized discharge education on discharge teaching quality and recovery outcomes in patients after lung cancer surgery. Eligible participants will be randomly assigned in a 1:1 ratio to either an intervention group or a control group. The control group will receive routine discharge education, including verbal instructions and a standardized printed discharge booklet. The intervention group will receive the same routine education plus an AI-generated personalized discharge guidance plan based on individual clinical and care-related information. All AI-generated content will be reviewed by a responsible nurse before being provided to participants. The primary outcome is the quality of discharge teaching measured on the day of discharge. Secondary outcomes include self-efficacy for postoperative rehabilitation management and quality of life assessed one month after discharge.

Read the detailed description

This is a single-center, prospective, single-blind randomized controlled trial designed to evaluate whether AI-personalized discharge education can improve discharge teaching quality and postoperative recovery outcomes among patients undergoing surgery for lung cancer. A total of 156 eligible participants will be randomly assigned in a 1:1 ratio to an intervention group or a control group.

Participants in the control group will receive routine discharge care, including verbal education provided by nursing staff and a standardized printed discharge education booklet covering medication use, wound care, respiratory exercises, physical activity, diet, follow-up, and other routine postoperative care.

Participants in the intervention group will receive routine discharge care plus AI-personalized discharge education. Within 24 hours before discharge, relevant patient information will be entered into a structured system, including surgical approach, extent of lung resection, pain score, dyspnea score, comorbidities, discharge medications, home care conditions, educational level, smoking history, and postoperative complications. A large language model will then generate an individualized discharge guidance document. The guidance will include medication instructions, respiratory rehabilitation exercises, wound and activity management, follow-up planning, and warning signs requiring medical attention. All AI-generated content will be reviewed and approved by a responsible nurse before being delivered to the participant or caregiver.

The primary outcome is discharge teaching quality, assessed using the Quality of Discharge Teaching Scale (QDTS) on the day of discharge after the intervention. Secondary outcomes include self-efficacy for postoperative rehabilitation management, assessed using the SESPRM-LC scale, and quality of life, assessed using the Functional Assessment of Cancer Therapy-Lung (FACT-L) scale, both measured one month after discharge.

The study will also explore the relationships among discharge teaching quality, self-efficacy, and quality of life, including the potential mediating role of self-efficacy.

02

Conditions studied

  • Lung Cancer (Diagnosis)

Keywords

  • Artificial Intelligence
  • Personalized Discharge Education
  • Postoperative Recovery
  • Discharge Teaching
  • Self-Efficacy
  • Quality of Life
03

In context

Lung Neoplasms

5,422 studies on the registry are indexed under Lung Neoplasms; 1,346 are open to participants now.

This study's planned enrollment of 156 is above the median of 60 across 3,656 interventional studies indexed under Lung Neoplasms.

Browse Lung Neoplasms studies →

Lead sponsor

Xiamen University is the lead sponsor of 26 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. confirmed primary lung cancer and underwent radical lung cancer surgery by thoracoscopic or open approach, including lobectomy, pneumonectomy, or wedge resection.
  2. Age 18 to 80 years.
  3. Clinical stage I to III.
  4. No distant organ .
  5. Clinically stable after surgery, conscious, and able to perform basic listening, speaking, and reading activities, with planned discharge to home for recovery.
  6. The participant or primary caregiver is able to use a smartphone and WeChat.
  7. Able and willing to provide and voluntarily participate in the study.

Exclusion criteria

Exclusion Criteria:

  1. Recurrent lung cancer or previous treatment with targeted therapy, chemotherapy, or radiotherapy.
  2. Severe aphasia, cognitive impairment ( \<24), or psychiatric disorders that prevent independent completion of study questionnaires.
  3. Severe cardiac, hepatic, or renal dysfunction, or another malignant tumor.
  4. Severe postoperative complications requiring prolonged hospitalization, such as bronchopleural fistula or major bleeding.
  5. Participation in another interventional clinical study.
  6. Unable to complete the 1-month follow-up because of travel or residence outside the study area after discharge.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
156 participants (estimated)

Study arms

  • Experimental
    AI-Personalized Discharge Education

    Participants receive routine discharge education plus AI-personalized discharge guidance. The personalized guidance is generated based on individual clinical and care-related information and is reviewed by a responsible nurse before being provided to the participant or caregiver.

    Behavioral: AI-Personalized Discharge Education · Behavioral: Routine Discharge Education

  • Active comparator
    Routine Discharge Education

    Participants receive routine discharge education, including verbal instructions from nursing staff and a standardized printed discharge education booklet covering medication use, wound care, respiratory exercises, physical activity, diet, follow-up, and related postoperative care.

    Behavioral: Routine Discharge Education

Interventions

  • BehavioralAI-Personalized Discharge Education

    Participants receive an individualized discharge guidance plan generated by an artificial intelligence system based on clinical and care-related information, including surgical approach, extent of lung resection, pain and dyspnea scores, comorbidities, discharge medications, home care conditions, educational level, smoking history, and postoperative complications. The guidance includes medication instructions, respiratory exercises, wound and activity management, follow-up planning, and warning signs requiring medical attention. All AI-generated content is reviewed by a responsible nurse before being provided to the participant or caregiver.

  • BehavioralRoutine Discharge Education

    Participants receive routine discharge education provided by nursing staff, including verbal instructions and a standardized printed discharge booklet covering medication use, wound care, respiratory exercises, physical activity, diet, follow-up, and other routine postoperative care.

06

What researchers measure

Primary outcomes

  1. Quality of Discharge Teaching Scale (QDTS) Total Score

    Discharge teaching quality will be assessed using the Quality of Discharge Teaching Scale (QDTS). The QDTS contains 24 items scored from 0 to 10, with a total score ranging from 0 to 240. Higher scores indicate better quality of discharge teaching.

    Time frame: On the day of discharge, immediately after the intervention

Secondary outcomes

  1. Self-Efficacy for Postoperative Rehabilitation Management (SESPRM-LC) Total Score

    Self-efficacy for postoperative rehabilitation management will be assessed using the SESPRM-LC scale. The scale contains 27 items scored from 1 to 5, with a total score ranging from 27 to 135. Higher scores indicate greater self-efficacy.

    Time frame: 1 month after discharge

  2. Quality of Life Measured by the Functional Assessment of Cancer Therapy-Lung (FACT-L)

    Quality of life will be assessed using the Functional Assessment of Cancer Therapy-Lung (FACT-L). Higher scores indicate better quality of life.

    Time frame: 1 month after discharge

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Individual participant data are not planned to be shared.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Oct 2026, 2 months after the start.

Of 864 non-industry interventional studies with no phase under Lung Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 68. This study's planned 2 months is below that.

Counting every sponsor, half of 915 studies reached it within 34 months; a quarter within 15 and three quarters within 67.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2026
First posted
Sep 18, 2026
StartActual
Aug 15, 2026
Primary completionEst.
Oct 15, 2026
CompletionEst.
Nov 15, 2026
Last update
Sep 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07827183
Lead sponsor
Xiamen University
Responsible party
Xi Huang (Assistant Professor, Xiamen University) — Principal investigator
First posted
Sep 18, 2026
Start date
Aug 15, 2026
Primary completion
Oct 15, 2026 (estimated)
Completion
Nov 15, 2026 (estimated)
Last update
Sep 18, 2026

Study contacts

Weiguang Zhou, Master's
Contact
254402969@qq.com
+86 13624449503
Yang Liu, PhD
principal investigator · Xiamen University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion